Memantine
- Generic Name
- Memantine
- Brand Names
- Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK
- Drug Type
- Small Molecule
- Chemical Formula
- C12H21N
- CAS Number
- 19982-08-2
- Unique Ingredient Identifier
- W8O17SJF3T
- Background
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...
- Indication
Memantine is used to manage moderate to severe Alzheimer's dementia .
...
- Associated Conditions
- Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 17
- Registration Number
- NCT00674219
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Study of Memantine to Treat Huntington's Disease
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Jody Corey-Bloom, MD, PhD
- Target Recruit Count
- 50
- Registration Number
- NCT00652457
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Memantine and Antipsychotics Use
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Merz Pharmaceuticals GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT00649220
- Locations
- 🇩🇪
Alexianer Hospital, Krefeld, North-Rhine-Westphalia, Germany
Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT00646204
- Locations
- 🇺🇸
PDCMDC 6550 Fannin, Suite 1801, Houston, Texas, United States
Memantine and Intensive Speech-Language Therapy in Aphasia
- Conditions
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2008-03-21
- Lead Sponsor
- Gabinete Berthier y Martínez
- Target Recruit Count
- 28
- Registration Number
- NCT00640198
- Locations
- 🇪🇸
Gabinete Berthier y Martínez and Centro de Investigaciones Médico-Sanitarias (CIMES) University of Malaga, Malaga, Spain
Memantine Therapy for Multiple Sclerosis
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2012-06-08
- Target Recruit Count
- 20
- Registration Number
- NCT00638833
- Locations
- 🇪🇸
Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
Memantine for Spasticity in MS Patients
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 21
- Registration Number
- NCT00638027
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 75
- Registration Number
- NCT00630500
- Locations
- 🇸🇪
Clinical Memory Research Unit, Neuropsychiatric Clinic, University Hospital Malmo, Malmo, Sweden
🇳🇴Stavanger University Hospital, Old Age Psychiatry Clinic, Stavanger, Norway
🇬🇧Mental Health Unit, Epping, Essex, United Kingdom
Family History Study of Alcohol Consumption Using Memantine
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Yale University
- Target Recruit Count
- 111
- Registration Number
- NCT00630955
- Locations
- 🇺🇸
CMHC, New Haven, Connecticut, United States
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
- Conditions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Tiffany Chow, MD
- Target Recruit Count
- 17
- Registration Number
- NCT00594737
- Locations
- 🇨🇦
Baycrest, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.